menu
    • menu

    Company profile for Rgenix

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Rgenix is a privately held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix’s founding scientists at Rockefeller University, and now exclusively licensed to Rgenix, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tu...
    Rgenix is a privately held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Rgenix’s founding scientists at Rockefeller University, and now exclusively licensed to Rgenix, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    RgenixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    310 E 67th St, Suite 1-12‎ New York, NY
    Telephone
    Telephone
    (646) 856-9261
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://rgenix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/rgenix/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/rgenix

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors
    RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors

    30 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210930005340/en

    BUSINESSWIRE
    30 Sep 2021
    Share Share
    RGENIX Presents Biomarker and Efficacy Results from Phase 1of RGX-104
    RGENIX Presents Biomarker and Efficacy Results from Phase 1of RGX-104

    22 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200622005088/en

    BUSINESSWIRE
    22 Jun 2020
    Share Share
    RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019
    RGENIX Presents Results from Preclinical Safety and Efficacy Studies of RGX-019

    22 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200622005089/en

    BUSINESSWIRE
    22 Jun 2020
    Share Share
    RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS
    RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS

    29 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200529005040/en

    BUSINESSWIRE
    29 May 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search